Home/Hedge Fund Intelligence/Taysha Gene Therapies, Inc.
Nasdaq: TSHAStockForm 13F30 Jun 2026

Hedge funds that hold Taysha Gene Therapies, Inc. Shs Nasdaq: TSHA

Shs · CUSIP 877619106 · who reports it, how much, and how much it matters to them

31 of the 720 hedge fund managers we track reported shares of Taysha Gene Therapies, Inc. (Nasdaq: TSHA) on Form 13F for 30 June 2026. Between them they reported USD 689m. The largest position belongs to Avoro Capital Advisors, at USD 163m. The manager with the most riding on it is Octagon Capital Advisors, where it is 5.9% of the reported book.

Managers reporting it31of 720 we track
Value they reportUSD 689mshares only, 30 Jun 2026
Funds they run368with a file on PPLI.com
Largest positionUSD 163mAvoro Capital Advisors
Typical weight0.0%median share of a manager's book
Heaviest weight5.9%Octagon Capital Advisors

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

31 managers, USD 689m between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Taysha Gene Therapies, Inc., largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Avoro Capital Advisors1 fund on PPLI.comUSD 163m1.5%
2Ra Capital Management1 fund on PPLI.comUSD 160m1.4%
3RTW Investments2 funds on PPLI.comUSD 92m0.8%
4Octagon Capital Advisors1 fund on PPLI.comUSD 66m5.9%
5Polar Capital LLP26 funds on PPLI.comUSD 35m0.1%
6D. E. Shaw & Co.15 funds on PPLI.comUSD 30m0.0%
7Baker Bros. Advisors2 funds on PPLI.comUSD 27m0.1%
8Casdin Capital3 funds on PPLI.comUSD 22m1.1%
9Farallon Capital Management56 funds on PPLI.comUSD 15m0.1%
10Millennium Management6 funds on PPLI.comUSD 14m0.0%
11Orbimed Advisors1 fund on PPLI.comUSD 14m0.3%
12Citadel Advisors32 funds on PPLI.comUSD 10m0.0%
13Palo Alto Investors6 funds on PPLI.comUSD 9.5m1.3%
14Squarepoint Ops7 funds on PPLI.comUSD 3.9m0.0%
15Acuta Capital Partners2 funds on PPLI.comUSD 3.8m2.7%
16Adage Capital Management1 fund on PPLI.comUSD 3.8m0.0%
17Holocene Advisors2 funds on PPLI.comUSD 3.5m0.0%
18Burkehill Global Management5 funds on PPLI.comUSD 3.4m0.1%
19Moore Capital Management7 funds on PPLI.comUSD 2.4m0.0%
20Sphera Funds Management1 fund on PPLI.comUSD 1.7m0.2%
21Two Sigma Investments35 funds on PPLI.comUSD 1.6m0.0%
22Balyasny Asset Management25 funds on PPLI.comUSD 1.3m0.0%
23Wexford Capital8 funds on PPLI.comUSD 1.1m0.1%
24Persistent Asset Partners10 funds on PPLI.comUSD 909,0000.3%
25Aquatic Capital Management3 funds on PPLI.comUSD 737,0000.0%
26Engineers Gate Manager1 fund on PPLI.comUSD 709,0000.0%
27Prelude Capital Management9 funds on PPLI.comUSD 670,0000.0%
28J. Goldman & Co.1 fund on PPLI.comUSD 459,0000.0%
29Weiss Asset Management5 funds on PPLI.comUSD 130,0000.0%
30Magnetar Financial93 funds on PPLI.comUSD 78,1450.0%
31The Quarry1 fund on PPLI.comUSD 3,2690.0%
Next: where it matters most
Where it matters most

For Octagon Capital Advisors it is 5.9% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Octagon Capital AdvisorsUSD 66m5.9%
2Acuta Capital PartnersUSD 3.8m2.7%
3Avoro Capital AdvisorsUSD 163m1.5%
4Ra Capital ManagementUSD 160m1.4%
5Palo Alto InvestorsUSD 9.5m1.3%
6Casdin CapitalUSD 22m1.1%
7RTW InvestmentsUSD 92m0.8%
8Persistent Asset PartnersUSD 909,0000.3%
9Orbimed AdvisorsUSD 14m0.3%
10Sphera Funds ManagementUSD 1.7m0.2%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Taysha Gene Therapies, Inc.

What is the ticker symbol of Taysha Gene Therapies, Inc.?

Taysha Gene Therapies, Inc. trades under the symbol TSHA on the Nasdaq. Its CUSIP, the code used on Form 13F, is 877619106.

Which hedge funds own Taysha Gene Therapies, Inc. (Nasdaq: TSHA)?

31 of the 720 hedge fund managers PPLI.com tracks reported Taysha Gene Therapies, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Avoro Capital Advisors (USD 163m), Ra Capital Management (USD 160m), RTW Investments (USD 92m), Octagon Capital Advisors (USD 66m) and Polar Capital LLP (USD 35m).

How many hedge funds hold Taysha Gene Therapies, Inc.?

31 managers in our coverage reported it, and between them they run 368 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Taysha Gene Therapies, Inc.?

Octagon Capital Advisors, where the position was 5.9% of the reported 13F book at 30 June 2026.

Does this show who is short Taysha Gene Therapies, Inc.?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Taysha Gene Therapies, Inc. or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.